Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

22/05/2024 - Investor Day

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

227.5 CHF

Average target price

279.4 CHF

Spread / Average Target

+22.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-3.27%	203B
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+30.61%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.17%	239B
NOVARTIS AG	+9.38%	211B
AMGEN INC.	+10.77%	171B
PFIZER, INC.	+0.10%	163B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:02:24 16/05/2024 pm IST			5-day change	1st Jan Change
236.6 ^CHF	+4.02%		+5.06%	-3.27%

10:16am	Roche shares boosted by good results in obesity treatment	CF
10:08am	Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial	DJ

Roche shares boosted by good results in obesity treatment	01:46pm	CF
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial	01:38pm	DJ
Roche shares gain on obesity drug results from early-stage trial	12:55pm	RE
Roche Says Investigational Obesity Drug Reduces Weight in Early-stage Study	11:24am	MT
Swiss Equities Advance as Cool US Inflation Data Boosts Sentiment	15/05	MT
Roche: HPV self-sampling test approved by the FDA	15/05	CF
Roche Wins US FDA Approval for HPV Self-collection Diagnostic Tool	15/05	MT
Roche says FDA approves HPV self-test in US	15/05	RE
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer	15/05	CI
ROCHE HOLDINGS AG : UBS remains Neutral	14/05	ZD
Wegovy weight loss sustained for four years in trial, Novo Nordisk says	14/05	RE
Lonza Affirms FY24 Sales Outlook, Raises Mid-term Growth Guidance	14/05	MT
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	10/05	MT
Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs	07/05	CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating	06/05	ZD
Swiss Equities Close in Red Amid Inflation Spotlight	29/04	MT
Roche Holding AG: slimming down	29/04
Roche: positive opinion from CHMP for subcutaneous Ocrevus	29/04	CF
European Medicines Agency Committee Backs Roche's Subcutaneous Injection for Multiple Sclerosis	29/04	MT
Roche: positive CHMP opinion for Alecensa	26/04	CF
Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU	26/04	MT
The specter of stagflation rears its ugly head again	25/04
ROCHE : Barclays lowers target price	25/04	CF
Scholz pledges further support for the pharmaceutical industry	25/04	DP
ROCHE HOLDINGS AG : UBS remains Neutral	25/04	ZD